Epilepsy

Transcranial magnetic stimulation for the treatment of epilepsy

Abstract Background Epilepsy is a highly prevalent neurological condition characterised by repeated unprovoked seizures with various aetiologies. Although antiepileptic medications produce clinical improvement in many individuals, nearly a third of individuals have drug‐resistant epilepsy that carries significant morbidity and mortality, and even individuals who have clinical improvement from antiepileptic medications often report iatrogenic symptoms. There […]

Share

Antidepressants for people with epilepsy and depression

Abstract Background Depressive disorders are the most common psychiatric comorbidity in people with epilepsy, affecting around one‐third, with a significant negative impact on quality of life. There is concern that people may not be receiving appropriate treatment for their depression because of uncertainty regarding which antidepressant or class works best, and the perceived risk of […]

Share

Anti‐seizure medications for Lennox‐Gastaut syndrome

Abstract Background Lennox‐Gastaut syndrome (LGS) is an age‐specific epilepsy syndrome characterised by multiple seizure types, including drop seizures. LGS has a characteristic electroencephalogram, an onset before age eight years and an association with drug resistance. This is an updated version of the Cochrane Review published in 2013. Objectives To assess the efficacy and tolerability of […]

Share

Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents

Abstract Background This is an updated version of the Cochrane Review previously published in 2019. Absence seizures (AS) are brief epileptic seizures which present in childhood and adolescence. Depending on clinical features and electroencephalogram (EEG) findings they are divided into typical, atypical absences, and absences with special features. Typical absences are characterised by sudden loss […]

Share

Gabapentin add‐on treatment for drug‐resistant focal epilepsy

Abstract Background This is an updated version of the Cochrane Review previously published in 2018. Epilepsy is a common neurological disorder characterised by recurrent seizures. Most people with epilepsy have a good prognosis and their seizures are well controlled by a single antiepileptic drug, but up to 30% develop drug‐resistant epilepsy, especially people with focal […]

Share

Rufinamide add‐on therapy for drug‐resistant epilepsy

Abstract Background Epilepsy is a central nervous system disorder (neurological disorder). Epileptic seizures are the result of excessive and abnormal cortical nerve cell electrical activity in the brain. Despite the development of more than 10 new antiepileptic drugs (AEDs) since the early 2000s, approximately a third of people with epilepsy remain resistant to pharmacotherapy, often […]

Share

Strategies for improving adherence to antiepileptic drug treatment in patients with epilepsy

Abstract Background Poor adherence to antiepileptic medication is associated with increased mortality, morbidity and healthcare costs. In this review, we focus on interventions designed and tested in randomised controlled trials (RCTs) and quasi‐RCTs to assist people with adherence to antiepileptic medication. This is an update of a Cochrane review first published in 2011, and last […]

Share

Pharmacological treatment for continuous spike-wave during slow wave sleep syndrome and Landau-Kleffner Syndrome

Abstract Background Continuous spike‐wave during slow wave sleep syndrome (CSWS) and Landau‐Kleffner syndrome (LKS) are two epileptic encephalopathies that present with neurocognitive regression, aphasia, and clinical seizures, typically presenting in children around five years of age. The pathophysiology of these conditions is not completely understood. Some studies suggest a common origin for both. No systematic […]

Share

Psychological treatments for people with epilepsy

Abstract Background Given the significant impact epilepsy may have on the health‐related quality of life (HRQOL) of individuals with epilepsy and their families, there is increasing clinical interest in evidence‐based psychological treatments, aimed at enhancing psychological and seizure‐related outcomes for this group. This is an updated version of the original Cochrane Review published in Issue 10, […]

Share

Vigabatrin for refractory partial epilepsy

Abstract Background This is an updated version of the original Cochrane Review published in 2008 and updated in 2013. Epilepsy is a common neurological condition which affects up to 1% of the population. Approximately 30% of people with epilepsy do not respond to treatment with currently available drugs. The majority of these people have focal […]

Share
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share